Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1 2Phase 3 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Neoplasm Metastasis 33Leukemia, Myeloid, Acute 24Melanoma 14Colorectal Neoplasms 14Breast Neoplasms 14Multiple Myeloma 13Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Pancreatic Neoplasms 10Lymphoma, Follicular 10Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large B-Cell, Diffuse 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, B-Cell, Marginal Zone 6Stomach Neoplasms 5Sarcoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, B-Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Unspecified Adult Solid Tumor, Protocol Specific 4

Interventions

Cyclophosphamide 8fludarabine phosphate 7Peripheral Blood Stem Cell Transplantation 6Filgrastim 6Cytarabine 5Azacitidine 5Tacrolimus 4Etoposide 4Specimen Handling 3Radiotherapy 3Doxorubicin 3ruxolitinib 2perifosine 2fludarabine 2aldesleukin 2Vincristine 2Tretinoin 2Sorafenib 2Sirolimus 2Mycophenolic Acid 2Melphalan 2Decitabine 2Clofarabine 2Bortezomib 2Biopsy 24-phenylbutyric acid 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2venetoclax 1trametinib 1sonidegib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Myelodysplastic-Myeloproliferative Diseases × Biopsy × Clear all
NCT06034470 2026-05-07

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

Fred Hutchinson Cancer Center

Phase 1 Active not recruiting
30 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT05549661 2026-02-23

Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms

Mayo Clinic

Phase 1 Recruiting
25 enrolled
MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡